PER 2.50% 8.2¢ percheron therapeutics limited

atl1102 update, page-12

  1. 169 Posts.
    interesting times ahead. Teva didn't want to take that extra mile to sort out the toxic effects of atl-1102. They had copaxone under trial at the same time and they finally decided on copaxone. Now Teva is in a spot of bother, having lost the patent rights to copaxone after a lengthy court battle. The patent rights expire next year.As well Teva suffered a loss last financial year.This time around Teva has to jostle with other pharma if it wants ATL1102.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.2¢
Change
0.002(2.50%)
Mkt cap ! $73.92M
Open High Low Value Volume
8.0¢ 8.2¢ 7.9¢ $16.80K 210.0K

Buyers (Bids)

No. Vol. Price($)
1 24999 7.9¢
 

Sellers (Offers)

Price($) Vol. No.
8.3¢ 31992 1
View Market Depth
Last trade - 16.10pm 06/09/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.